Filing Flows › Amneal Pharmaceuticals (AMRX) › Takeover & LBO
Is Amneal Pharmaceuticals (AMRX) a takeover target?
A leveraged buyout does not work for Amneal Pharmaceuticals on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Historically 3.0% of companies with its figures were bought within a year (0.59× the average). Latest signal (2026-06-29): Merger proxy (DEFM14A).
Why a leveraged buyout does not fit
The buyout model needs Amneal Pharmaceuticals' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
The odds, from history
Historically 3.0% of companies with its figures were bought within a year (0.59× the average). Its figures put it in decile 2 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Rumors and deal signals
- 2026-06-29 · DEFM14A · Merger proxy (DEFM14A)
Amneal Pharmaceuticals' latest quarter
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
Questions
Is Amneal Pharmaceuticals being acquired?
The latest signal on file is from 2026-06-29: Merger proxy (DEFM14A). A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Amneal Pharmaceuticals?
A leveraged buyout does not work for Amneal Pharmaceuticals on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.